Recent advancements in mRNA cancer vaccines have highlighted the potential of personalised medicines, but this brings unique challenges in production and scale-up. James Zaremba, sales director at automation specialist COPA-DATA, explains how specialised software can help to navigate the complexities of this new generation of pharmaceutical manufacturing.
Key insights:
- A digital transformation to contend with biopharma's challenges will need to be implemented to monitor processes and manage flexibility throughout the manufacturing process of personalised medicine.
- Automation and smart software platforms are becoming more commonplace in pharma manufacturing and will be essential in the new generation of therapeutics.
- A common issue raised against personalised medicine is the collection and storage of patient’s genetic information, so protecting confidentiality should be a fundamental concept in production.
- The zenon Module Type Package (MTP) Suite can optimise production efficiency by allowing a task to be subdivided into small modules that can be standardised.
Messenger RNA (mRNA) is an underpinning part of vital biological processes, but interest is growing in its potential therapeutic applications. mRNA was the foundation of the most profitable and important vaccines to date — the ground-breaking Covid-19 vaccines — and now attention is turning to how this technology can treat other diseases.